Companies: 10,795·Total market cap: $144.5T
AbCellera Biologics Inc.

AbCellera Biologics Inc.

ABCLNASDAQHealthcare● Active
$5.42
$-0.20(-3.56%)
Market Cap$1.7B
P/E Ratio
52W High$6.79
52W Low$2.33

AbCellera Biologics Inc. (ABCL) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

abcl · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 11 Wall Street analysts in the past 3 months

SellBuy

Buy

11 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
9
Hold
2
Sell
0
Strong Sell
0
Total: 11 · Buy rate: 81.8%

12-Month Price Target

High

$8.00

Consensus

$7.50

+39.3% upside

Low

$7.00

Median: $7.5 · Last Close: $5.38

The AbCellera Biologics Inc. (ABCL) analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month ABCL price target is $7.50, representing +39.3% upside from the current price of $5.38.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $8 (39.3%)

Consensus Target

$7.50

39.3% upside

High Target

$8

48.6%

Low Target

$7

30.0%

Current Price

$5.38

as of today

Based on analyst price targets, the ABCL stock price prediction for the next 12 months ranges from $7 to $8. The consensus ABCL price forecast of $7.50 implies 39.3% upside from the current price of $5.38.

Short-Term Price Prediction

Bull

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$5.655.00%

1-day model range: $5.58–$5.72. Peak: $5.72 (+5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$3-35.7%
2028$3-48.3%
2029$2-53.9%
2030$2-56.6%
2031-58.0%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

64%7%29%
9Buy
1Neutral
4Sell
RSI (14)62.5Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · ABCL · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$5.85SELL
MA 10$5.83SELL
MA 20$5.24BUY
MA 50$4.47BUY
MA 100$4.01BUY
MA 200$4.22BUY
Current $ABCL · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$5.73SELL
EMA 10$5.67SELL
EMA 20$5.36BUY
EMA 50$4.73BUY
EMA 100$4.34BUY
EMA 200$4.09BUY
Current $ABCL · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Leerink Partners2025-11-07
Downgrade ↓
OutperformMarket Perform
Stifel2025-08-08
Maintains
BuyBuy
Keybanc2025-07-14
Maintains
OverweightOverweight
Truist Securities2025-05-16
Maintains
BuyBuy
Stifel2025-05-09
Maintains
BuyBuy
Keybanc2025-04-16
Maintains
OverweightOverweight
Benchmark2025-03-03
Maintains
HoldHold
Stifel2025-02-28
Maintains
BuyBuy
Keybanc2025-01-08
Maintains
OverweightOverweight
Stifel2024-11-05
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on AbCellera Biologics Inc. (ABCL) stock. Of the recent 38 rating actions, 1 were upgrades and 2 were downgrades. 11 analysts currently cover ABCL.

Analyst Recommendation Trends

Buy ratings00
Hold ratings11
Sell ratings00

ABCL analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$32M

↓ 4.1% YoY

Revenue Next Year

$31M

↓ 3.4% YoY

EPS This Year

$-0.59

EPS Next Year

$-0.64

↑ 9.2% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ABCL EPS of $-0.59 for the current fiscal year, based on estimates from 5 analysts. The ABCL revenue forecast is $32M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ABCL stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ABCL price target is $7.50 (+39.3% upside), with an analyst consensus of Buy.

The ABCL short-term stock prediction for tomorrow is $5.65 (+5.00%). The ABCL stock price prediction for 2027 estimates an average of $3. The ABCL stock prediction for 2030 projects a range of $2–$3.

AbCellera Biologics Inc. trades on NASDAQ under the ticker ABCL. The ABCL stock outlook for 2027 is broadly positive, supported by a Buy consensus among 82% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ABCL forecast · 8 questions

According to 11 Wall Street analysts, the average 12-month ABCL price target is $7.50, with a high forecast of $8.00 and a low of $7.00. The median price target is shown in the chart above when available. This implies +39.3% potential upside from the current price of $5.38.

ABCL price targetWhat is ABCL price targetABCL analyst price targetABCL 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.